{"transactions":[{"id":743529,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":39752,"kind":"person","name":"Luo Ying","position":1,"cik":"0001959160","reported_name":"Luo Ying","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T20:13:08.000Z","date":"2026-06-08","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 120,000 shares of the Issuer's common stock, 25% of which will vest on June 8, 2027, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":120000,"derivative":{"exercise_price":6.05,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001140361-26-024784","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126024784/form4.xml","form_type":"4"}},{"id":788761,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":39752,"kind":"person","name":"Luo Ying","position":1,"cik":"0001959160","reported_name":"Luo Ying","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-08T01:58:29.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":10136,"price":8.04,"value":81493.44,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.071. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2565226,"source":{"system":"sec-edgar","filing":"0001140361-26-019658","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126019658/form4.xml","form_type":"4"}},{"id":788760,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":39752,"kind":"person","name":"Luo Ying","position":1,"cik":"0001959160","reported_name":"Luo Ying","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-08T01:58:29.000Z","date":"2026-05-05","kind":"sale","planned":true,"acquired":false,"shares":179,"price":8.01,"value":1433.79,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025."}],"balance_after":2575362,"source":{"system":"sec-edgar","filing":"0001140361-26-019658","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126019658/form4.xml","form_type":"4"}},{"id":1431651,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":39752,"kind":"person","name":"Luo Ying","position":1,"cik":"0001959160","reported_name":"Luo Ying","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-17T00:56:01.000Z","date":"2024-08-14","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 26,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through August 14, 2025, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":26000,"derivative":{"exercise_price":9.98,"expiration_date":"2034-08-14","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001140361-24-037707","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124037707/form4.xml","form_type":"4"}},{"id":1731646,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":39752,"kind":"person","name":"Luo Ying","position":1,"cik":"0001959160","reported_name":"Luo Ying","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-23T00:55:53.000Z","date":"2023-11-20","kind":"grant","planned":false,"acquired":true,"shares":2262755,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Beijing Continent terminated its 2021 Stock Incentive Plan (the \"2021 Plan\") and each option (a \"BC Option\") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Beijing Continent terminated its 2021 Stock Incentive Plan (the \"2021 Plan\") and each option (a \"BC Option\") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options are vested in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Beijing Continent terminated its 2021 Stock Incentive Plan (the \"2021 Plan\") and each option (a \"BC Option\") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan."}],"balance_after":2262755,"derivative":{"exercise_price":0.75,"expiration_date":"2030-10-31","underlying":"Common Stock","underlying_shares":2262755},"source":{"system":"sec-edgar","filing":"0001140361-23-054522","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123054522/form4.xml","form_type":"4"}},{"id":1731645,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":39752,"kind":"person","name":"Luo Ying","position":1,"cik":"0001959160","reported_name":"Luo Ying","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-23T00:55:53.000Z","date":"2023-11-20","kind":"grant","planned":false,"acquired":true,"shares":3350897,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Beijing Continent terminated its 2021 Stock Incentive Plan (the \"2021 Plan\") and each option (a \"BC Option\") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Beijing Continent terminated its 2021 Stock Incentive Plan (the \"2021 Plan\") and each option (a \"BC Option\") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options are vested in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Beijing Continent terminated its 2021 Stock Incentive Plan (the \"2021 Plan\") and each option (a \"BC Option\") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan."}],"balance_after":3350897,"derivative":{"exercise_price":0.75,"expiration_date":"2030-10-31","underlying":"Common Stock","underlying_shares":3350897},"source":{"system":"sec-edgar","filing":"0001140361-23-054522","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123054522/form4.xml","form_type":"4"}},{"id":1731644,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":39752,"kind":"person","name":"Luo Ying","position":1,"cik":"0001959160","reported_name":"Luo Ying","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-11-23T00:55:53.000Z","date":"2023-10-30","kind":"other","planned":false,"acquired":true,"shares":2840376,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the number of shares of common stock of the Issuer received by the spouse of the Reporting Person in exchange for the shares of Aaring Limited, a company incorporated under the laws of Hong Kong with limited liability, held by the spouse of the Reporting Person pursuant to that certain Business Combination Agreement, dated as of December 26, 2022 and as amended on March 29, 2023 and August 30, 2023 (the \"Business Combination Agreement\"), by and among Catalyst Biosciences, Inc., a Delaware corporation, GNI USA, Inc., a Delaware corporation, GNI Group Ltd., a company incorporated under the laws of Japan with limited liability,"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[cont'd from FN 1] GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability, Shanghai Genomics, Inc., a company organized under the laws of the People's Republic of China, the Minority Holders (as defined therein) and Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares. Pursuant to the terms of the Business Combination Agreement, on October 30, 2023, the Issuer acquired an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China (\"Beijing Continent\")."}],"balance_after":2840376,"source":{"system":"sec-edgar","filing":"0001140361-23-054522","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123054522/form4.xml","form_type":"4"}},{"id":1752579,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":39752,"kind":"person","name":"Luo Ying","position":1,"cik":"0001959160","reported_name":"Luo Ying","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-01T10:15:35.000Z","date":"2023-10-31","kind":"grant","planned":false,"acquired":true,"shares":1866,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest as to one-third on each of the first, second and third anniversaries of October 31, 2023, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":1866,"derivative":{"exercise_price":6.93,"expiration_date":"2033-10-31","underlying":"Common Stock","underlying_shares":1866},"source":{"system":"sec-edgar","filing":"0001140361-23-050620","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123050620/form4.xml","form_type":"4"}}]}